Key Highlights

  • Net loss for the third quarter of 2026 was USD 46.5 million, or USD 0.46 per share, against USD 17.5 million, or USD 0.25, a year earlier, as non-cash Fair Value changes cost USD 28.6 million.
  • Loss from operations was USD 19.2 million against USD 8.3 million, with Research and Development more than doubling to USD 14.5 million from USD 6.4 million on gene therapy Manufacturing and clinical costs.
  • License and collaboration Revenue fell to USD 1.1 million from USD 3.1 million, about 63.1% lower by simple calculation, because less research and development service work was reimbursed under the Viatris agreement.
  • Cash and cash equivalents were USD 89.0 million on September 30, 2026, and management said that is sufficient to fund operations for at least the next 12 months.

A USD 28.6 Million Fair Value Charge Inflates the Loss

Opus Genetics (NASDAQ:IRD) filed its Quarterly Report on November 10, 2026 for the period ended September 30, 2026. The clinical-stage company develops gene therapies for inherited retinal diseases. Its net loss of USD 46.5 million was far larger than its USD 19.2 million operating loss because of a USD 28.6 million expense from remeasuring financial instruments, made up of USD 27.5 million on warrants and USD 1.1 million on convertible notes. The filing ties such changes to swings in the company's share price, and the expense is non-cash. A year earlier the equivalent charge was USD 9.5 million. Other income, net, was USD 1.4 million.

Spending Rises as Phase 3 Prepares to Dose

Research and development rose USD 8.1 million to USD 14.5 million, of which manufacturing costs for the inherited retinal disease programs added USD 5.5 million and clinical costs USD 1.7 million, partly offset by lower clinical costs for its phentolamine ophthalmic solution programs. General and administrative expense rose to USD 5.9 million on higher compensation. Nine-month net loss was USD 120.1 million, or USD 1.27 per share, against USD 33.1 million, or USD 0.59, and the fair value charge for nine months was USD 72.8 million. Revenue is mostly reimbursement from Viatris and a small Royalty on RYZUMVI sales, so it can fluctuate with how much service work is performed.

Debt, ATM Capacity and the OPGx-LCA5 Timeline

Funding has come from many sources. A February 2026 private Placement raised about USD 25.0 million, and an April 2026 note purchase agreement with Oberland Capital provides access to up to USD 155.0 million, with an initial USD 35.0 million funded on April 21, 2026. A new at-the-market program of up to USD 125.0 million became available in August, with no shares sold under it so far. Phase 3 enrollment of 8 participants for OPGx-LCA5 was completed in August, dosing is expected in the fourth quarter of 2026 and topline data by the end of 2027.

Where Things Stand

Opus Genetics (NASDAQ:IRD) lost USD 46.5 million largely because warrants and notes were revalued by USD 28.6 million, a non-cash item, while the operating loss was USD 19.2 million. That operating loss still more than doubled as gene therapy manufacturing and trial work ramped, and revenue fell. Cash of USD 89.0 million and Debt capacity give room, but the structure adds interest and share dilution risk. Next markers are the start of Phase 3 dosing in the fourth quarter of 2026, use of the Oberland tranches or the new at-the-market program, and topline data due by the end of 2027.